CCM
GRCE

Campbell Capital Management’s Grace Therapeutics GRCE Stock Holding History

Campbell Capital Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-625
Closed -$18K – 64
2021
Q1 		$18K Buy
+625
New +$21.7K 0.01% 53

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Campbell Capital Management's GRCE Position: Q2 2021 in Review

Campbell Capital Management sold out of Grace Therapeutics (GRCE) in Q2 2021, closing a stake of 625 shares — an estimated $18K sold.

Campbell Capital Management first reported a position in GRCE in Q1 2021 and held it in 1 quarter. The position peaked at $18K in Q1 2021. 26 funds tracked by Wall St. Rank hold GRCE as of Q2 2021.

  • Campbell Capital Management reported no remaining Grace Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Campbell Capital Management sold 625 Grace Therapeutics shares in Q2 2021, an estimated $18K.
  • Campbell Capital Management first reported a position in Grace Therapeutics in Q1 2021 and held it in 1 quarter.
  • Campbell Capital Management's Grace Therapeutics position peaked at $18K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2021.

Based on Campbell Capital Management's 13F filing for Q2 2021, filed 9 Jul 2021.